The precise identification of the types and respective roles of the tumor-associated myeloid cells, which include tumor-associated Mϕs (TAMs), neutrophils, dendritic cells, and myeloid-derived suppressor cells, is under intensive investigation. Although tumor-associated myeloid cells may contribute to tumor cell eradication by virtue of their effector functions, they are retained to fulfill predominantly protumorigenic roles. It follows that depletion of tumor-associated myeloid cells represents one of the currently pursued therapeutic options in advanced malignancies. In that regard, RG7155/emactuzumab, a specific anti-CSF-1R humanized Ab, has been reported recently to deplete CSF-1R + TAMs, in association with objective clinical responses in patients with advanced cancer. Because RG7155/emactuzumab has also been shown to deplete blood non-classic CD14 dim/− CD16 ++ monocytes, which in large part include the CD16 ++ slan + monocytes, we asked whether RG7155/emactuzumab could target tumor-associated slan + cells. In this study, we confirmed that slan + cells localize only to metastatic tumor-draining lymph nodes, not to primary tumors or distant metastases in patients with different types of carcinoma. Notably, by cell scoring on serial sections, we found that slan + cells represent a minor fraction of the total CSF-1R + cell pool, suggesting that slan + cells potentially represent minor targets of anti-CSF-1R therapy. Therefore, a protumorigenic role for slan + cells, such as that of CSF-1R + TAMs, based on our current data, remains questionable.

Potential contribution of tumor-associated slan + cells as anti-CSF-1R targets in human carcinoma

Lonardi S.;Micheletti A.;Vermi W.;
2018-01-01

Abstract

The precise identification of the types and respective roles of the tumor-associated myeloid cells, which include tumor-associated Mϕs (TAMs), neutrophils, dendritic cells, and myeloid-derived suppressor cells, is under intensive investigation. Although tumor-associated myeloid cells may contribute to tumor cell eradication by virtue of their effector functions, they are retained to fulfill predominantly protumorigenic roles. It follows that depletion of tumor-associated myeloid cells represents one of the currently pursued therapeutic options in advanced malignancies. In that regard, RG7155/emactuzumab, a specific anti-CSF-1R humanized Ab, has been reported recently to deplete CSF-1R + TAMs, in association with objective clinical responses in patients with advanced cancer. Because RG7155/emactuzumab has also been shown to deplete blood non-classic CD14 dim/− CD16 ++ monocytes, which in large part include the CD16 ++ slan + monocytes, we asked whether RG7155/emactuzumab could target tumor-associated slan + cells. In this study, we confirmed that slan + cells localize only to metastatic tumor-draining lymph nodes, not to primary tumors or distant metastases in patients with different types of carcinoma. Notably, by cell scoring on serial sections, we found that slan + cells represent a minor fraction of the total CSF-1R + cell pool, suggesting that slan + cells potentially represent minor targets of anti-CSF-1R therapy. Therefore, a protumorigenic role for slan + cells, such as that of CSF-1R + TAMs, based on our current data, remains questionable.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/537889
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact